Healthcare
Live Price
Offline$87.97
+0.93% today
1Y Change
-4.56%
Window
Jun 23, 2025 → Jun 5, 2026
Coverage: 240 bars · Jun 23, 2025 → Jun 5, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Zimmer Biomet Holdings, Inc. (ZBH) is a Healthcare stock with a market cap of $16.00B and listed on NYSE. The stock last traded around $87.97 and down 4.6% across the available one-year price window (Jun 23, 2025 → Jun 5, 2026). Baseline metrics include revenue growth of +7.2%, EPS growth of -20.0%, a dividend yield of 1.2%. What stands out right now is revenue +7.2%, EPS -20.0%, free cash flow +28.9% with operating margin 15.6% and ROIC 5.0%. The dividend is present but secondary, with a yield around 1.2%. Valuation is more restrained than many high-expectation growth names at P/E 21.2 and price/sales 1.9. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines ZBH price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
ZBH
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
ZBH Max Drawdown
-26.12%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for ZBH and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$8.2B
+7.2% YoY
FY Net Income
$705.1M
-22.1% YoY
Free Cash Flow
$1.4B
+24.3% YoY
Revenue Growth
+7.2%
EPS Growth
-20.0%
Gross Margin
70.0%
Net Margin
9.1%
Income statement
USD
| Metric | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Revenue | 6.8B | 6.9B | 7.4B | 7.7B | 8.2B |
| Gross Profit | 4.9B | 4.9B | 5.3B | 5.5B | 5.7B |
| Operating Income | 1.0B | 1.2B | 1.5B | 1.5B | 1.4B |
| EBITDA | 2.0B | 2.0B | 2.4B | 2.5B | 2.5B |
| Net Income | 402M | 232M | 1.0B | 905M | 705M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Cash & Equivalents | 378M | 376M | 416M | 526M | 592M |
| Total Assets | 23.5B | 21.1B | 21.5B | 21.4B | 23.1B |
| Total Liabilities | 10.8B | 9.0B | 9.0B | 8.9B | 10.4B |
| Shareholder Equity | — | — | — | — | — |
| Total Debt | 7.1B | 5.9B | 5.9B | 6.2B | 7.5B |
| Net Debt | — | — | — | — | — |
Cash flow positioning
2026 Full Year
Operating Cash Flow
1.6B
-12.4% YoY
Capital Expenditures
—
Free Cash Flow
1.4B
+24.3% YoY
Key ratios
Gross Margin
70.0%
Operating Margin
15.6%
Net Margin
9.1%
ROE
5.8%
Debt / Equity
0.51x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.